Swiss Biotech Association’s Post

CEBioForum 2024 Last year at the Polonium Foundation meeting in Paris I had a chance to get to know the BioForum Director Magdalena Kulczycka,Ph.D. Today I had a real pleasure to participate in the Central European BioForum meeting in Warsaw, in short: a networking meeting for biotech companies, start-ups, research institutes. It gave me a new biotechnological perspective on the drug design and clinical trials business. If you have never participated, I guess you can count for the CEBioForum 2025 edition, it's an ongoing event since 2000. The goal is also ongoing: how to enable the biotech lab innovation to get to the market.

This summarizes the essence of our Life Science fund. We invest in life saving science.

If you're looking to understand how to achieve successful CMC development for Live Biotherapeutic Products, don't miss the compelling presentation by biose industrie at the PRI conference. For more in-depth information or direct inquiries, feel free to contact us directly. #CMCDevelopment #bioseindustrie #LiveBiotherapeuticProducts #PRIConference

Join Blake Mandell from Transcend Therapeutics at the upcoming Fierce Biotech Summit on Sept 30 - Oct 1 in Boston as he shares his expertise in groundbreaking biotech innovations and advancements. Register now and save up to $500 with the Early Bird Rate: https://ow.ly/uTAE50SyYgy Learn, Network and Connect over two jam-packed days with 500+ industry leaders and gain valuable insights into the future landscape of biotech. Stay Updated on all our events by following Fierce Life Sciences Events #FierceBiotechSummit #WeAreFierce #FierceBiotech #FierceBiotechSummit #BiotechInnovation #LifeSciences #PharmaIndustry #BiotechLeaders #Biotech2024 #BiotechTrends

Excited to announce that I will be attending Bioeurope Spring, one of the most prominent biotech partnering conferences! Looking forward to connecting with industry leaders, exploring innovative collaborations, and staying up-to-date with the latest trends in the life sciences sector. If you'll be there too, I would love to meet up and discuss potential opportunities. See you at #BioEuropeSpring! #MilliporeCTDMO #Drugconjugate #smallmolecule #HPAPI #linkerpayload"

🧬𝐁𝐈𝐎𝐓𝐄𝐂𝐇 𝐒𝐓𝐀𝐑𝐓𝐄𝐑 𝐊𝐈𝐓 – 𝐈𝐍𝐓𝐄𝐋𝐋𝐄𝐂𝐓𝐔𝐀𝐋 𝐏𝐑𝐎𝐏𝐄𝐑𝐓𝐘 𝐑𝐈𝐆𝐇𝐓𝐒 Today Francesca D. is presenting the sixth Biotech Starter Kit’s factsheet we published this Monday. ➡️ Download our sixth factsheet at: https://lnkd.in/eFkAxX5h and watch the video below ↓

A major step in strengthening IMIDomics Inc. as a leader in the discovery and development of new treatments for immune-mediated inflammatory diseases. #IMIDs #PrecisionMedicine #Patients #DrugDevelopment

Join Ed Harnaga from Pfizer at the upcoming Fierce Biotech Summit on Sept 30 - Oct 1 in Boston as he shares his expertise in groundbreaking biotech innovations and advancements. Register now and save up to $500 with the Early Bird Rate: https://ow.ly/uTAE50SyYgy Learn, Network and Connect over two jam-packed days with 500+ industry leaders and gain valuable insights into the future landscape of biotech. Stay Updated on all our events by following Fierce Life Sciences Events #FierceBiotechSummit #WeAreFierce #FierceBiotech #FierceBiotechSummit #BiotechInnovation #LifeSciences #PharmaIndustry #BiotechLeaders #Biotech2024 #BiotechTrends

Overcoming preclinical hurdles is a big topic in the oncology drug development space. Bispecific antibodies (BsAbs) is a promising frontier in targeted cancer therapies, yet the journey from concept to clinic is fraught with many challenges. Unfortunately, only about 10-15% of BsAB drugs successfully make it to the clinic. A significant portion of these failures can be attributed to the inadequacies of preclinical models that fail to predict clinical outcomes accurately. Selecting appropriate preclinical models is paramount because they provide essential insights into the drug's efficacy and safety profile. In this white paper, we discuss the rising importance of BsAbs as anti-cancer drugs, while emphasizing the importance of implementing an integrated suite of preclinical solutions to accelerate the development of BsAb candidates. A case study of HanX’s BsAb, HX009, is presented to highlight the integrated selection of in vitro and in vivo preclinical solutions used to comprehensively characterize this innovative BsAb. Importantly, these studies were instrumental in supporting the clearance of the company’s IND application submitted to the FDA. At Crown Bioscience, we understand these challenges all too well. By leveraging our integrated solutions approach, combining cutting-edge technology with deep expertise, researchers can enhance the predictability of their preclinical trials, reducing the risk of late-stage failures and accelerating the development of life-saving therapies. #oncology #BsAbs #BispecificAntibodies #DrugDevelopment #PreclinicalModels  https://lnkd.in/dzZg36zA

🔬 With RNA constantly changing and innovating, we thought we should too! A new take on your traditional conference showcase 💰 If you're active in the RNA space (or a fan of shark tank 🦈), let's connect and have a chat #rna #biotech #investment #mrna #RNALeaders